BDY Bradley Pharmaceuticals

FAIRFIELD, N.J., Aug. 9 /PRNewswire-FirstCall/ -- The independent Special Committee of the Board of Directors of Bradley Pharmaceuticals, Inc. (NYSE:BDY) today announced that it has received preliminary bids for a possible sale of the Company in connection with its previously announced consideration of strategic alternatives. As announced previously, the Special Committee has retained Deutsche Bank Securities Inc. as its independent financial advisor. Following receipt of these preliminary bids, the Special Committee has determined that it will continue to pursue a possible sale of the Company. All bids are non-binding and subject to various conditions. No assurance can be given that any of these bidders or any other potential bidder will continue to express an interest in a transaction with the Company or that any transaction will result from any bid or be consummated. The Special Committee undertakes no obligation to update the information set forth in this press release or any other information related to the Special Committee and its work. Other Information: About Bradley Pharmaceuticals, Inc. Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty pharmaceutical company and markets to niche physician specialties in the U.S. and international markets. Bradley's success is based upon its core strengths in marketing and sales, which enable the company to Commercialize brands that fill unmet patient and physician needs; Develop new products through life cycle management; and In-License phase II and phase III drugs with long-term intellectual property protection that upon approval leverage Bradley's marketing and sales expertise to increase shareholder value. Bradley Pharmaceuticals is comprised of Doak Dermatologics, specializing in therapies for dermatology and podiatry; Kenwood Therapeutics, providing gastroenterology, OB/GYN, respiratory and other internal medicine brands; and A. Aarons, which markets authorized generic versions of Doak and Kenwood therapies. Safe Harbor for Forward-Looking Statements: This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that address activities, events or developments that Bradley expects, believes or anticipates will or may occur in the future, such as Bradley's plans to in-license, develop and launch new and enhanced products with long-term intellectual property protection or other significant barriers to market entry, sales and earnings estimates, other predictions of financial performance, launches by Bradley of new products, market acceptance of Bradley's products, and the achievement of initiatives to enhance corporate governance and long-term shareholder value. Forward-looking statements are based on Bradley's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond Bradley's control. These risks and uncertainties include Bradley's ability to: launch VEREGEN(TM) at the end of 2007; predict the safety and efficacy of ELESTRIN(TM) and VEREGEN(TM) in a commercial setting; estimate sales; maintain adequate inventory levels; implement the returns and inventory optimization plan timely, if at all; reduce product returns; comply with the restrictive covenants under its credit facility; refinance its credit facility; access the capital markets on attractive terms or at all; favorably resolve the pending SEC informal inquiry; maintain or increase sales of its products; or effectively react to other risks and uncertainties described from time to time in Bradley's SEC filings, such as fluctuation of quarterly financial results, estimation of product returns, chargebacks, rebates and allowances, concentration of customers, reliance on third party manufacturers and suppliers, litigation or other proceedings (including the pending class action and shareholder derivative lawsuits), government regulation and stock price volatility. Further, Bradley cannot accurately predict the impact on its business of the approval, introduction, or expansion by competitors of generic or therapeutically equivalent or comparable versions of Bradley's products or of any other competing products. In addition, actual results may differ materially from those projected. Bradley undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. DATASOURCE: Bradley Pharmaceuticals, Inc. CONTACT: Investor Relations, Anthony Griffo of Bradley Pharmaceuticals, Inc., +1-973-882-1505, ext. 313 Web site: http://www.bradpharm.com/

Copyright